MARKET

INVA

INVA

Innoviva
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.67
+0.16
+1.18%
Opening 15:12 08/10 EDT
OPEN
13.55
PREV CLOSE
13.51
HIGH
13.72
LOW
13.50
VOLUME
198.66K
TURNOVER
--
52 WEEK HIGH
15.62
52 WEEK LOW
7.58
MARKET CAP
1.39B
P/E (TTM)
6.73
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Underperform

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average INVA stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.

EPS

INVA News

More
Did Hedge Funds Make The Right Call On Innoviva, Inc. (INVA)?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which
Insider Monkey · 6d ago
Innoviva Reports Second Quarter 2020 Financial Results
Innoviva, Inc. (NASDAQ: INVA) (the Company) today reported financial results for the second quarter ended June 30, 2020.
Business Wire · 07/29 20:05
Innoviva Is A Hold
Seeking Alpha - Article · 07/10 07:40
2 Underperforming Holdings to Reduce
GuruFocus.com · 07/06 17:58
Here is What Hedge Funds Think About Innoviva, Inc. (INVA)
Insider Monkey · 06/24 01:34
Has Innoviva (INVA) Outpaced Other Medical Stocks This Year?
Zacks · 06/23 16:30
Innoviva (INVA) Looks Good: Stock Adds 8.9% in Session
Zacks · 06/23 13:50
Entasis Therapeutics Completes Closing of Second Tranche of $35M Private Placement with Innoviva
GlobeNewswire · 06/11 21:05

Industry

Pharmaceuticals
+0.08%
Pharmaceuticals & Medical Research
+0.15%

Hot Stocks

Symbol
Price
%Change

About INVA

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.
More

Webull offers kinds of Innoviva Inc stock information, including NASDAQ:INVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INVA stock methods without spending real money on the virtual paper trading platform.